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Summary. Submucosal tumors of the gastrointestinal 
tract (G1 tract) mainly consist of gastrointestinal 
mesenchymal tumors (GIMTs) that are distributed in the 
G1 tract from the esophagus through the rectum. GIMTs 
include myogenic tumors, neurogenic tumors and 
gastrointestinal stromal tumors (GISTs). The term 
"GIST" is now preferentially used for the tumors that 
express CD34 and KIT. GIMTs are composed of spindle 
or epithelioid cells, and 20% to 30% show malignant 
behavior, including peritonea1 dissemination and 
hematogenous metastasis. KIT expression and mutations 
in the c-kit gene are found only in GISTs, but not in 
myogenic or neurogenic tumors. Mutation in the c-kit 
gene is associated with aggressive features and poor 
prognosis, and malignant GISTs frequently have 
mutations in the c-kit gene. The clinicopathological 
features of GISTs with or without c-kit mutations are 
markedly different. Therefore, GIMTs may be divided 
into four major categories based on histochemical and 
genetic data: myogenic tumors; neurogenic tumors; 
GISTs with c-kit mutation; and GISTs without c-kit 
mutation. The origin of GISTs is not fully understood. 
However, phenotypical resemblance to the interstitial 
cells of Cajal (ICCs) and gain-of-function mutations in 
the c-kit gene may suggest origin from ICCs andlor 
multipotential mesenchymal cells that differentiate into 
ICCs. 
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Cajal; NSE: neuron-specific enolase; SCF: stem cell 
factor. 
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Comments: The term "Gastrointestinal Stromal Turnor 
(GIST)" is occasionally used for all types of stromal 
tumors in the gastrointestinal tract. However, in this 
review, "GIST" is used for the group of rnesenchymal 
tumors that specially express CD34 andlor KIT. These 
tumors were previously classified as Gastrointestinal 
Stromal Tumor-uncommitted type. In this review the 
term "Gastrointestinal Mesenchymal Tumor (GIMT)" is 
used for rnesenchymal origin-stromal tumors, including 
GISTs, myogenic tumors, and neurogenic tumors. 
Introduction 
Mesenchymal tumors in the gastrointestinal (GI) 
tract show similar clinical presentation. Traditionally, 
gastrointestinal mesenchymal turnors (GIMTs) have 
been classified as smooth muscle tumors (leiomyomas, 
cellular leiomyomas, or leiornyosarcomas) or neurogenic 
tumors (schwannomas) based on their morphological 
resemblance either to smooth muscle or neurogenic cells 
(schwann cells). Currently, GIMTs are divided into three 
major categories including myogenic tumors 
(leiomyomas or leiomyosarcomas), neurogenic tumors 
(i.e. schwannomas), and gastrointestinal stromal tumors 
(GISTs) according to the expression of marker proteins 
and ultrastructural characteristics (see the following 
pages and Batts and Barwick, 1996; Lechago and Genta, 
1996; Rosai, 1996; Miettinen et al., 1999b). 
Although the term "GIST" may be used for all 
mesenchymal tumors in the G1 tract, including myogenic 
tumors, neurogenic tumors, and gastrointestinal strornal 
tumors-uncommitted type, in this review, the term is 
used to designate gastrointestinal stromal tumors- 
uncommitted type which express CD34 andlor KIT 
(CD117) proteins (Monihan et al., 1994; Miettinen et al., 
1995, 1999b; Hirota et al., 1998; Kindblom et al., 1998; 
Sarlomo-Rikala et al., 1998; Seidal and Edvardsson, 
1999). GISTs appear to be a heterogeneous group of 
mesenchymal cell-origin tumors but show similar 
histological features and clinical behavior, and thus are 
considered to have similar oncological backgrounds 
(Miettinen et al., 1999b). The two major problems in the 








